A Phase 3 Study of RMC-6236 versus Standard Therapy for People with Previously Treated Metastatic Pancreatic Cancer

Full Title

RASolute 302: A Phase 3 Multicenter, Open-label, Randomized Study of RMC-6236 versus Investigator’s Choice of Standard of Care Therapy in Patients with Previously Treated Metastatic Pancreatic Ductal Adenocarcinoma (PDAC) (Advarra IRB)

Purpose

Researchers are comparing RMC-6236 with standard therapy in people with advanced pancreatic cancer. The people in this study have pancreatic cancer that has metastasized (spread) and keeps growing even after treatment.

RMC-6236 targets the protein made by a mutated (altered) form of the KRAS gene. The KRAS protein sends signals that cause cancer cells to grow. RMC-6236 is designed to prevent the KRAS protein from sending these signals. Blocking this action may slow or stop the growth of cancer cells.

If you join this study, you will be randomly assigned to get one of these treatments:

• RMC-6236, which is taken orally (by mouth)
• Standard chemotherapy, which is given intravenously (by vein).

Contact

For more information or to see if you can join this study, please call Dr. Eileen O’Reilly’s office at 646-888-4182.